Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study Felip, E., Altorki, N. K., Zhou, C., Vallieres, E., Vynnychenko, I. O., Akopov, A., Martinez-Marti, A., Chella, A., Bondarenko, I., Ursol, G., Levchenko, E., Kislov, N., Liersch, R., Belleli, R., McNally, V. A., Bennett, E., Gitlitz, B. J., Wakelee, H. ELSEVIER. 2022: S71
View details for DOI 10.1016/j.annonc.2022.02.090
View details for Web of Science ID 000778453100082